Abstract: The present disclosure relates to a method and device for warning a user of a vehicle with an energy storage unit against an energy shortage. According to the present disclosure, an energy quantity is determined that is stored in the energy storage unit at a branching point of a path driven on by the vehicle, and a direction option of the vehicle at the branching point is selected. Further, the one route is determined that is associated with the direction option and starts at the branching point, on which the vehicle is able to reach with the lowest expected energy requirement an energy charging location at which the energy storage unit can be charged. The energy requirement is compared with the energy quantity, and a warning indication is outputted with which the user is warned against the direction option if the energy requirement is greater than the energy quantity.

Abstract: The invention relates to a rail vehicle brake system comprising a conditioning device, having at least one disc brake per axle, the conditioning device having a control device. The conditioning device is formed having at least one wagon control unit and at least one coupling unit for selective actuation of the at least one disc brake per axle. The invention further relates to a conditioning device and to a method for operating a conditioning device, and to a method for deicing and/or for preventing icing of a brake unit of a rail vehicle brake system.

Abstract: The present disclosure relates to a method and device for warning a user of a vehicle with an energy storage unit against an energy shortage. According to the present disclosure, an energy quantity is determined that is stored in the energy storage unit at a branching point of a path driven on by the vehicle, and a direction option of the vehicle at the branching point is selected. Further, the one route is determined that is associated with the direction option and starts at the branching point, on which the vehicle is able to reach with the lowest expected energy requirement an energy charging location at which the energy storage unit can be charged. The energy requirement is compared with the energy quantity, and a warning indication is outputted with which the user is warned against the direction option if the energy requirement is greater than the energy quantity.

Abstract: The present disclosure relates to a method for reproducing broadcast programs by a broadcast receiver device. The method includes: receiving a broadcast program by a receiving unit, checking, if an actual program content of the received broadcast program corresponds to a predetermined program content, by a calculating unit, buffering the received broadcast program in the reproduction buffer unit, as long as the actual program content corresponds to the predetermined program content, reproducing the buffered broadcast program by a reproduction unit with a reproduction velocity, which is lower than a receiving velocity, with which the buffered broadcast program was received, and tuning the receiving unit to another broadcast program, so that instead of the received broadcast program the other broadcast program will be received, as soon as one of the actual program content does not correspond to the predetermined program content.

Abstract: The invention relates to a rail vehicle brake system comprising a conditioning device, having at least one disc brake per axle, the conditioning device having a control device. The conditioning device is formed having at least one wagon control unit and at least one coupling unit for selective actuation of the at least one disc brake per axle. The invention further relates to a conditioning device and to a method for operating a conditioning device, and to a method for deicing and/or for preventing icing of a brake unit of a rail vehicle brake system.

Abstract: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.

Abstract: The present invention relates to pyridazinone derivatives of general formula I, wherein the groups A, G and R1 are as defined in the application, the tautomers thereof, stereoisomers thereof, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.

Abstract: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.

Abstract: The present invention relates to pyridazinone derivatives of general formula I, wherein the groups A, G and R1 are as defined in the application, the tautomers thereof, stereoisomers thereof, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.

Abstract: The present invention relates to kits for measuring nitric oxide synthase activity.

Abstract: New compounds of formula 1 are provided which by virtue of their pharmaceutical activity as PI3-kinase modulators may be used in the therapeutic field for the treatment of inflammatory or allergic diseases. Examples of these include inflammatory and allergic respiratory complaints, inflammatory diseases of the gastro-intestinal tract and motor apparatus, inflammatory and allergic skin diseases, inflammatory eye diseases, diseases of the nasal mucosa, inflammatory or allergic conditions involving autoimmune reactions or inflammations of the kidney.

Abstract: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD. Formula (I), wherein A is selected from among a single bond, ?CH—, —CH2—, —O—, —S—, and —NH—; wherein n is 1, 2 or 3; wherein Z is C or N, the other variables are as defined in the claims, as well as in form of their acid addition salts with pharmacologically acceptable acids.

Abstract: A pharmaceutical composition comprising a compound of formula 1 wherein: n is 1 or 2; R1 is hydrogen, C1-C4-alkyl, halogen, OH, or —O—C1-C4-alkyl; R2 is hydrogen, C1-C4-alkyl, halogen, OH, or —O—C1-C4-alkyl; R3 is hydrogen, C1-C4-alkyl, OH, halogen, —O—C1-C4-alkyl, —O—C1-C4-alkylene-COOH, or —O—C1-C4-alkylene-CO—O—C1-C4-alkyl, or an acid addition salt thereof with a pharmacologically acceptable acid, or a solvate or hydrate thereof; and a pharmaceutically acceptable excipient or carrier, and methods for using the pharmaceutical formulation in the treatment of chronic obstructive pulmonary disease (COPD).

Abstract: The present invention relates to a method for determining NO enzymatically and its use for the identification of substances which can modulate a nitric oxide synthase activity.

Abstract: A pharmaceutical composition comprising a compound of formula 1 wherein: n is 1 or 2; R1 is hydrogen, C1-C4-alkyl, halogen, OH, or —O—C1-C4-alkyl; R2 is hydrogen, C1-C4-alkyl, halogen, OH, or —O—C1-C4-alkyl; R3 is hydrogen, C1-C4-alkyl, OH, halogen, —O—C1-C4-alkyl, —O—C1-C4-alkylene-COOH, or —O—C1-C4-alkylene-CO—O—C1-C4-alkyl, or an acid addition salt thereof with a pharmacologically acceptable acid, or a solvate or hydrate thereof; and a pharmaceutically acceptable excipient or carrier, and methods for using the pharmaceutical formulation in the treatment of chronic obstructive pulmonary disease (COPD).

Abstract: The present invention relates to methods for detection of nitric oxide (NO) by measuring guanosine monophosphate (cGMP).

Abstract: A pharmaceutical composition comprising a compound of formula 1 wherein: n is 1 or 2; R1 is hydrogen, C1-C4-alkyl, halogen, OH, or —O—C1-C4-alkyl; R2 is hydrogen, C1-C4-alkyl, halogen, OH, or —O—C1-C4-alkyl; R3 is hydrogen, C1-C4-alkyl, OH, halogen, —O—C1-C4-alkyl, —O—C1-C4-alkylene-COOH, or —O—C1-C4-alkylene-CO—O—C1-C4-alkyl, or an acid addition salt thereof with a pharmacologically acceptable acid, or a solvate or hydrate thereof; and a pharmaceutically acceptable excipient or carrier, and methods for using the pharmaceutical formulation in the treatment of chronic obstructive pulmonary disease (COPD).

Abstract: The present invention relates to the use of dihydropteridinones of formula 1 wherein the groups X, R1, R2, R3, R4, R5, R6 and R7 have the meanings given in the claims and specification, for the preparation of a medicament for the treatment of respiratory diseases.